CVRx Launches a new Barostim™ Programmer
12 juil. 2022 08h30 HE
|
CVRx, Inc.
MINNEAPOLIS, July 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure, has...
CVRx to Present at the William Blair 42nd Annual Growth Stock Conference
23 mai 2022 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, May 23, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System
09 mai 2022 08h30 HE
|
CVRx, Inc.
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s...
CVRx Reports First Quarter 2022 Financial and Operating Results
25 avr. 2022 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, April 25, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CVRx to Report First Quarter 2022 Financial and Operating Results and Host Conference Call
12 avr. 2022 16h30 HE
|
CVRx, Inc.
MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
15 févr. 2022 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Feb. 15, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative...
CVRx to Report Fourth Quarter and Fiscal Year 2021 Financial Results on February 15, 2022
01 févr. 2022 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Feb. 01, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2021 Financial Results
10 janv. 2022 08h00 HE
|
CVRx, Inc.
MINNEAPOLIS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Present at the 40th Annual J.P. Morgan Healthcare Conference
21 déc. 2021 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Dec. 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference
16 nov. 2021 16h05 HE
|
CVRx, Inc.
MINNEAPOLIS, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...